{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:03:55Z","timestamp":1787497435446,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cca.2022.11.029","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T01:57:53Z","timestamp":1670551073000},"page":"97-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Cascadion\u2122 SM Clinical Analyzer: Evaluation of the whole blood immunosuppressants quantification and routine usability"],"prefix":"10.1016","volume":"539","author":[{"given":"Elise","family":"Mathieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Duterme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cca.2022.11.029_b0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","article-title":"Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy","volume":"56","author":"Taylor","year":"2005","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.cca.2022.11.029_b0010","first-page":"1","article-title":"Overview of therapeutic drug monitoring, Korean","volume":"24","author":"Kang","year":"2009","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.cca.2022.11.029_b0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2001.00365.x","article-title":"Immunosuppressant drugs - The role of therapeutic drug monitoring","volume":"52","author":"Johnston","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.cca.2022.11.029_b0020","first-page":"485","article-title":"A review on therapeutic drug monitoring of immunosuppressant drugs","volume":"14","author":"Mohammadpour","year":"2011","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/j.cca.2022.11.029_b0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.clinbiochem.2020.03.004","article-title":"After another decade: LC\u2013MS\/MS became routine in clinical diagnostics","volume":"82","author":"Seger","year":"2020","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cca.2022.11.029_b0030","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/FTD.0000000000000269","article-title":"Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: Recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive","volume":"38","author":"Seger","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2022.11.029_b0035","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.trac.2015.11.016","article-title":"Recent advances in therapeutic drug monitoring of immunosuppressive drugs","volume":"79","author":"Freudenberger","year":"2016","journal-title":"TrAC - Trends Anal. Chem."},{"key":"10.1016\/j.cca.2022.11.029_b0040","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cll.2016.07.001","article-title":"Liquid Chromatography-Tandem Mass Spectrometry: An Emerging Technology in the Toxicology Laboratory","volume":"36","author":"Zhang","year":"2016","journal-title":"Clin. Lab. Med."},{"key":"10.1016\/j.cca.2022.11.029_b0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.trac.2016.01.031","article-title":"Liquid chromatography tandem mass spectrometry for therapeutic drug monitoring of immunosuppressive drugs: Achievements, lessons and open issues","volume":"84","author":"Shipkova","year":"2016","journal-title":"TrAC - Trends Anal. Chem."},{"issue":"1","key":"10.1016\/j.cca.2022.11.029_b0050","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/dta.2290","article-title":"Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs","volume":"10","author":"Zhang","year":"2018","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.cca.2022.11.029_b0055","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cca.2013.11.023","article-title":"Common decision limits - The need for harmonised immunoassays","volume":"432","author":"Sturgeon","year":"2014","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.cca.2022.11.029_b0060","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/FTD.0000000000000191","article-title":"Long-term cross-validation of everolimus therapeutic drug monitoring assays: The zortracker study","volume":"37","author":"Schniedewind","year":"2015","journal-title":"Ther. Drug Monit."},{"issue":"10-11","key":"10.1016\/j.cca.2022.11.029_b0065","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.clinbiochem.2010.03.016","article-title":"Multi-center evaluation of a commercial Kit for tacrolimus determination by LC\/MS\/MS","volume":"43","author":"Napoli","year":"2010","journal-title":"Clin. Biochem."},{"issue":"1-2","key":"10.1016\/j.cca.2022.11.029_b0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cccn.2005.01.005","article-title":"Inter-laboratory differences in sirolimus results from six sirolimus testing centers using HPLC tandem mass spectrometry (LC\/MS\/MS)","volume":"355","author":"Wilson","year":"2005","journal-title":"Clin. Chim. Acta."},{"issue":"1","key":"10.1016\/j.cca.2022.11.029_b0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clinbiochem.2010.06.005","article-title":"Progress in automation of LC-MS in laboratory medicine","volume":"44","author":"Vogeser","year":"2011","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cca.2022.11.029_b0080","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.cca.2015.08.027","article-title":"Impact of automation on mass spectrometry","volume":"450","author":"Zhang","year":"2015","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.cca.2022.11.029_b0085","unstructured":"COFRAC, Guide technique d\u2019accr\u00e9ditation de v\u00e9rification (port\u00e9e A)\/validation (port\u00e9e B) des m\u00e9thodes en biologie m\u00e9dicale, SH GTA 04 (2015) 1\u2013191, https:\/\/tools.cofrac.fr\/documentation\/SH-GTA-04 (accessed 8 August 2022)."},{"key":"10.1016\/j.cca.2022.11.029_b0090","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.talanta.2013.03.048","article-title":"Ion suppression; A critical review on causes, evaluation, prevention and applications","volume":"115","author":"Furey","year":"2013","journal-title":"Talanta"},{"key":"10.1016\/j.cca.2022.11.029_b0095","unstructured":"US Food and Drug Administration (FDA), Bioanalytical Method Validation guidance for Industry (2018), 1-44, https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf (accessed 2 November 2022)."},{"key":"10.1016\/j.cca.2022.11.029_b0100","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1373\/clinchem.2004.043950","article-title":"Low hematocrit and serum albumin concentrations underlie the overestimation of tacrolimus concentrations by microparticle enzyme immunoassay versus liquid chromatography-tandem mass spectrometry","volume":"53","author":"Brown","year":"2005","journal-title":"Clin. Chem."},{"issue":"6","key":"10.1016\/j.cca.2022.11.029_b0105","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1248\/bpb.31.1250","article-title":"Use of sample hematocrit value to correct blood tacrolimus concentration derived by microparticle enzyme immunoassay","volume":"31","author":"Tomita","year":"2008","journal-title":"Biol. Pharm. Bull."},{"issue":"6","key":"10.1016\/j.cca.2022.11.029_b0110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.clinbiochem.2005.02.011","article-title":"Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods","volume":"38","author":"Akbas","year":"2005","journal-title":"Clin. Biochem."},{"issue":"8","key":"10.1016\/j.cca.2022.11.029_b0115","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1248\/bpb.25.1119","article-title":"False positive blood tacrolimus concentration in microparticle enzyme immunoassay","volume":"25","author":"Homma","year":"2002","journal-title":"Biol. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.cca.2022.11.029_b0120","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00007691-200208000-00008","article-title":"Interference of hematocrit in the tacrolimus II microparticle enzyme immunoassay","volume":"24","author":"Kuzuya","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.cca.2022.11.029_b0125","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1515\/cclm-2020-0848","article-title":"Evaluation of the first immunosuppressive drug assay available on a fully automated LC-MS\/MS-based clinical analyzer suggests a new era in laboratory medicine","volume":"59","author":"H\u00f6rber","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"10.1016\/j.cca.2022.11.029_b0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1258\/acb.2008.008135","article-title":"Use of a common standard improves the performance of liquid chromatography-tandem mass spectrometry methods for serum 25-hydroxyvitamin-D","volume":"46","author":"Carter","year":"2009","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.cca.2022.11.029_b0135","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1373\/clinchem.2013.209114","article-title":"Standardization of LC-MS for therapeutic drug monitoring of tacrolimus","volume":"59","author":"Annesley","year":"2013","journal-title":"Clin. Chem."},{"issue":"11","key":"10.1016\/j.cca.2022.11.029_b0140","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1515\/cclm-2021-1340","article-title":"Interlaboratory comparison study of immunosuppressant analysis using a fully automated LC-MS\/MS system","volume":"60","author":"Zahr","year":"2022","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898122013961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898122013961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:08:04Z","timestamp":1757862484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898122013961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":28,"alternative-id":["S0009898122013961"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2022.11.029","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cascadion\u2122 SM Clinical Analyzer: Evaluation of the whole blood immunosuppressants quantification and routine usability","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2022.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}